Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances...

EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib

Z Ezzoukhry, C Louandre, E Trécherel… - … journal of cancer, 2012 - Wiley Online Library
Sorafenib is currently the medical treatment of reference for hepatocellular carcinoma
(HCC), but it is not known whether sorafenib is equally active in all HCC. Here, our aim was …
被引用次数：173 相关文章 所有 9 个版本
[HTML] nature.com

[HTML][HTML] Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in …

RH Berndsen, A Weiss, UK Abdul, TJ Wong… - Scientific reports, 2017 - nature.com
Ruthenium-based compounds show strong potential as anti-cancer drugs and are being
investigated as alternatives to other well-established metal-based chemotherapeutics. The …
被引用次数：115 相关文章 所有 14 个版本

Caloric restriction: from soup to nuts

SR Spindler - Ageing research reviews, 2010 - Elsevier
Caloric restriction (CR), reduced protein, methionine, or tryptophan diets; and reduced
insulin and/or IGFI intracellular signaling can extend mean and/or maximum lifespan and …
被引用次数：211 相关文章 所有 6 个版本

Design of molecular hybrids of phthalimide-triazole agents with potent selective MCF-7/HepG2 cytotoxicity: Synthesis, EGFR inhibitory effect, and metabolic stability

SK Ihmaid, SY Alraqa, MR Aouad, A Aljuhani… - Bioorganic …, 2021 - Elsevier
This study reports an efficient and convenient click chemistry synthesis of a novel series of
phthalimide scaffold linked to 1, 2, 3 triazole ring and terminal lipophilic fragments …
被引用次数：42 相关文章 所有 4 个版本

From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now

RWC Pang, RTP Poon - Oncology, 2007 - karger.com
Hepatocellular carcinoma (HCC) is characterized as a highly chemoresistant cancer with no
effective systemic therapy. Despite surgical or locoregional therapies, prognosis remains …
被引用次数：257 相关文章 所有 11 个版本
[HTML] nih.gov

[HTML][HTML] Novel therapeutic strategies for targeting liver cancer stem cells

N Oishi, XW Wang - International Journal of Biological Sciences, 2011 - ncbi.nlm.nih.gov
The cancer stem cell (CSC) hypothesis was first proposed over 40 years ago. Advances in
CSC isolation were first achieved in hematological malignancies, with the first CSC …
被引用次数：191 相关文章 所有 16 个版本
[PDF] academia.edu

Label-free imaging of drug distribution and metabolism in colon cancer cells by Raman microscopy

SF El-Mashtoly, D Petersen, HK Yosef, A Mosig… - Analyst, 2014 - pubs.rsc.org
Targeted cancer therapies block cancer growth and spread using small molecules. Many
molecular targets for an epidermal growth factor receptor (EGFR) selectively compete with …
被引用次数：154 相关文章 所有 13 个版本
[PDF] academia.edu

EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer

A Huether, M Höpfner, V Baradari, D Schuppan… - Biochemical …, 2005 - Elsevier
Hepatocellular carcinoma (HCC) is one of the most common cancer-related causes of death
worldwide. In light of the very poor 5 year survival new therapeutic approaches are …
被引用次数：221 相关文章 所有 11 个版本
[HTML] gastrojournal.org

MUC15 inhibits dimerization of EGFR and PI3K–AKT signaling and is associated with aggressive hepatocellular carcinomas in patients

RY Wang, L Chen, HY Chen, L Hu, L Li, HY Sun… - Gastroenterology, 2013 - Elsevier
Background & Aims Aberrant expression of MUC15 correlates with development of
colorectal adenocarcinoma, and MUC15 has been reported to prevent trophoblast invasion …
被引用次数：133 相关文章 所有 6 个版本
[PDF] academia.edu

Pathogenesis of hepatocellular carcinoma and molecular therapies

B Mínguez, V Tovar, D Chiang… - Current opinion in …, 2009 - journals.lww.com
Pathogenesis of hepatocellular carcinoma and molecular thera... : Current Opinion in
Gastroenterology Pathogenesis of hepatocellular carcinoma and molecular therapies : Current …
被引用次数：198 相关文章 所有 9 个版本